News & Updates
Filter by Specialty:
Ixazomib dexamethasone a new treatment in the arsenal against RRMM
In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.
Ixazomib dexamethasone a new treatment in the arsenal against RRMM
18 Feb 2022
Clinician specialty does not contribute to worse outcomes in peripheral artery disease
Socioeconomic factors, but not clinician specialty, are associated with poorer outcomes among patients with peripheral artery disease (PAD), suggests a study.
Clinician specialty does not contribute to worse outcomes in peripheral artery disease
18 Feb 2022
Being physically active helps prevent NAFLD
Physical activity (PA) is associated with a lower prevalence of nonalcoholic fatty liver disease (NAFLD), with greater benefits for higher PA intensities, reveals a study. Better metabolic health, particularly lower waist circumference and insulin resistance, mediates this association.
